Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial
<p><strong>Background</p></strong> Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a proinflammatory cytokine overproduced in several inflammatory and autoimmune diseases, including axial spondyloarthritis. Namilumab is a human IgG1 monoclonal anti-GM-CSF antibod...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 语言: | English |
| 出版: |
Elsevier
2024
|
| _version_ | 1826316955206811648 |
|---|---|
| author | Worth, C Al-Mossawi, MH MacDonald, J Fisher, BA Chan, A Sengupta, R Packham, J Gaffney, K Gullick, N Cook, JA Corn, TH Teh, J Machado, PM Taylor, PC Bowness, P |
| author_facet | Worth, C Al-Mossawi, MH MacDonald, J Fisher, BA Chan, A Sengupta, R Packham, J Gaffney, K Gullick, N Cook, JA Corn, TH Teh, J Machado, PM Taylor, PC Bowness, P |
| author_sort | Worth, C |
| collection | OXFORD |
| description | <p><strong>Background</p></strong>
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a proinflammatory cytokine overproduced in several inflammatory and autoimmune diseases, including axial spondyloarthritis. Namilumab is a human IgG1 monoclonal anti-GM-CSF antibody that potently neutralises human GM-CSF. We aimed to assess the efficacy of namilumab in participants with moderate-to-severe active axial spondyloarthritis.
<p><strong>Methods</p></strong>
This proof-of-concept, randomised, double-blind, placebo-controlled, phase 2, Bayesian (NAMASTE) trial was done at nine hospitals in the UK. Participants aged 18–75 years with axial spondyloarthritis, meeting the Assessment in SpondyloArthritis international Society (ASAS) criteria and the ASAS-defined MRI criteria, with active disease as defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), were eligible. Those who had inadequately responded or had intolerance to previous treatment with an anti-TNF agent were included. Participants were randomly assigned (6:1) to receive subcutaneous namilumab 150 mg or placebo at weeks 0, 2, 6, and 10. Participants, site staff (except pharmacy staff), and central study staff were masked to treatment assignment. The primary endpoint was the proportion of participants who had an ASAS ≥20% improvement (ASAS20) clinical response at week 12 in the full analysis set (all randomly assigned participants). This trial is registered with ClinicalTrials.gov (NCT03622658).
<p><strong>Findings</p></strong>
From Sept 6, 2018, to July 25, 2019, 60 patients with moderate-to-severe active axial spondyloarthritis were assessed for eligibility and 42 were randomly assigned to receive namilumab (n=36) or placebo (n=six). The mean age of participants was 39·5 years (SD 13·3), 17 were women, 25 were men, 39 were White, and seven had previously received anti-TNF therapy. The primary endpoint was not met. At week 12, the proportion of patients who had an ASAS20 clinical response was lower in the namilumab group (14 of 36) than in the placebo group (three of six; estimated between-group difference 6·8%). The Bayesian posterior probability η was 0·72 (>0·927 suggests high clinical significance). The rates of any treatment-emergent adverse events in the namilumab group were similar to those in the placebo group (31 vs five).
<p><strong>Interpretation</p></strong>
Namilumab did not show efficacy compared with placebo in patients with active axial spondyloarthritis, but the treatment was generally well tolerated.
<p><strong>Funding</p></strong>
Izana Bioscience, NIHR Oxford Biomedical Research Centre (BRC), NIHR Birmingham BRC, and Clinical Research Facility. |
| first_indexed | 2024-09-25T04:13:14Z |
| format | Journal article |
| id | oxford-uuid:04df11d7-bd1c-4e8f-851e-56f70b7f4ae7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2025-02-19T04:30:57Z |
| publishDate | 2024 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:04df11d7-bd1c-4e8f-851e-56f70b7f4ae72025-01-08T12:08:47ZGranulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:04df11d7-bd1c-4e8f-851e-56f70b7f4ae7EnglishSymplectic ElementsElsevier2024Worth, CAl-Mossawi, MHMacDonald, JFisher, BAChan, ASengupta, RPackham, JGaffney, KGullick, NCook, JACorn, THTeh, JMachado, PMTaylor, PCBowness, P<p><strong>Background</p></strong> Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a proinflammatory cytokine overproduced in several inflammatory and autoimmune diseases, including axial spondyloarthritis. Namilumab is a human IgG1 monoclonal anti-GM-CSF antibody that potently neutralises human GM-CSF. We aimed to assess the efficacy of namilumab in participants with moderate-to-severe active axial spondyloarthritis. <p><strong>Methods</p></strong> This proof-of-concept, randomised, double-blind, placebo-controlled, phase 2, Bayesian (NAMASTE) trial was done at nine hospitals in the UK. Participants aged 18–75 years with axial spondyloarthritis, meeting the Assessment in SpondyloArthritis international Society (ASAS) criteria and the ASAS-defined MRI criteria, with active disease as defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), were eligible. Those who had inadequately responded or had intolerance to previous treatment with an anti-TNF agent were included. Participants were randomly assigned (6:1) to receive subcutaneous namilumab 150 mg or placebo at weeks 0, 2, 6, and 10. Participants, site staff (except pharmacy staff), and central study staff were masked to treatment assignment. The primary endpoint was the proportion of participants who had an ASAS ≥20% improvement (ASAS20) clinical response at week 12 in the full analysis set (all randomly assigned participants). This trial is registered with ClinicalTrials.gov (NCT03622658). <p><strong>Findings</p></strong> From Sept 6, 2018, to July 25, 2019, 60 patients with moderate-to-severe active axial spondyloarthritis were assessed for eligibility and 42 were randomly assigned to receive namilumab (n=36) or placebo (n=six). The mean age of participants was 39·5 years (SD 13·3), 17 were women, 25 were men, 39 were White, and seven had previously received anti-TNF therapy. The primary endpoint was not met. At week 12, the proportion of patients who had an ASAS20 clinical response was lower in the namilumab group (14 of 36) than in the placebo group (three of six; estimated between-group difference 6·8%). The Bayesian posterior probability η was 0·72 (>0·927 suggests high clinical significance). The rates of any treatment-emergent adverse events in the namilumab group were similar to those in the placebo group (31 vs five). <p><strong>Interpretation</p></strong> Namilumab did not show efficacy compared with placebo in patients with active axial spondyloarthritis, but the treatment was generally well tolerated. <p><strong>Funding</p></strong> Izana Bioscience, NIHR Oxford Biomedical Research Centre (BRC), NIHR Birmingham BRC, and Clinical Research Facility. |
| spellingShingle | Worth, C Al-Mossawi, MH MacDonald, J Fisher, BA Chan, A Sengupta, R Packham, J Gaffney, K Gullick, N Cook, JA Corn, TH Teh, J Machado, PM Taylor, PC Bowness, P Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial |
| title | Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial |
| title_full | Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial |
| title_fullStr | Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial |
| title_full_unstemmed | Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial |
| title_short | Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial |
| title_sort | granulocyte macrophage colony stimulating factor neutralisation in patients with axial spondyloarthritis in the uk namaste a randomised double blind placebo controlled phase 2 trial |
| work_keys_str_mv | AT worthc granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT almossawimh granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT macdonaldj granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT fisherba granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT chana granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT senguptar granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT packhamj granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT gaffneyk granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT gullickn granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT cookja granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT cornth granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT tehj granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT machadopm granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT taylorpc granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial AT bownessp granulocytemacrophagecolonystimulatingfactorneutralisationinpatientswithaxialspondyloarthritisintheuknamastearandomiseddoubleblindplacebocontrolledphase2trial |